8.3921

2.29% 0.1821

Adma Biologics Inc (ADMA)

Overview News Price History Option Chain Financials Discussions Forecast

Adma Biologics Inc stock is traded at $8.3921, with a volume of 585.33K. It is up +2.29% in the last 24 hours and up +1.55% over the past month. ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Previous Close:

$8.21

Open:

$8.26

24h Volume:

585.33K

Relative Volume:

0.09

Market Cap:

$1.94B

Revenue:

$509.86M

Net Income/Loss:

$165.35M

P/E Ratio:

12.38

EPS:

0.6779

Net Cash Flow:

$107.55M

1W Performance:

+4.20%

1M Performance:

+1.55%

6M Performance:

-57.43%

1Y Performance:

-59.64%

1-Day Range:

$8.23

$8.42

1-Week Range:

$8.02

$8.895

52-Week Range:

$7.2101

$20.97

Adma Biologics Inc Stock (ADMA) Company Profile

Name

Adma Biologics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(201) 478-5552

Address

C/O ADMA BIOLOGICS, INC., RAMSEY

Employee

647

Twitter

@AdmaBiologics

Next Earnings Date

2026-08-05

Latest SEC Filings

ADMA's Discussions on Twitter

Compare ADMA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADMA Adma Biologics Inc	8.39	1.90B	509.86M	165.35M	107.55M	0.6779
VRTX Vertex Pharmaceuticals Inc	450.91	112.92B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	613.49	64.18B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	889.69	55.57B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	286.56	37.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.92	32.71B	742.00K	-1.37B	-1.07B	-7.0731

Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Initiated	Canaccord Genuity	Buy
Mar-26-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-19-23	Resumed	Raymond James	Strong Buy
Oct-13-22	Initiated	Mizuho	Buy
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight
Jun-04-19	Initiated	Jefferies	Buy
Apr-15-19	Reiterated	H.C. Wainwright	Buy
Feb-07-19	Resumed	H.C. Wainwright	Buy
Dec-11-17	Reiterated	Maxim Group	Buy
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy
May-13-15	Reiterated	Maxim Group	Buy
Dec-08-14	Initiated	Oppenheimer	Outperform
Dec-01-14	Reiterated	Maxim Group	Buy

View All

Adma Biologics Inc Stock (ADMA) Latest News

07:06 AM

ADMA Biologics Fair Value call saved investors from 40% decline By Investing.com - Investing.com Canada

07:06 AM

Jun 14, 2026

ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 14, 2026

Jun 13, 2026

Lost Money on ADMA Biologics, Inc. (ADMA)? Join Class Action Before August 10, 2026Contact Levi & Korsinsky - ACCESS Newswire

Jun 13, 2026

Nomura VIP Small Cap Growth Series's ADMA Biologics Inc(ADMA) Holding History - GuruFocus

Jun 13, 2026

Jun 12, 2026

ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire

Jun 12, 2026

ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead the ADMA Biologics Class Action Lawsuit - The Malaysian Reserve

Jun 12, 2026

ADMA Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against ADMA Biologics, Inc. - PR Newswire

Jun 12, 2026

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - StreetInsider

Jun 12, 2026

ADMA Biologics Faces Securities Fraud Lawsuit - Intellectia AI

Jun 12, 2026

Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action - Benzinga

Jun 12, 2026

Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, - GlobeNewswire

Jun 12, 2026

DEADLINE ALERT for VIA, Z, and ADMA: The Law Offices of - GlobeNewswire

Jun 12, 2026

Law Offices of Frank R. Cruz Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action - Business Wire

Jun 12, 2026

$ADMA Class Action Alert: ADMA Biologics Channel Stuffing - GlobeNewswire

Jun 12, 2026

$ADMA Lawsuit: ADMA Biologics Channel Stuffing Allegations Trigger Securities Fraud Class ActionInvestors Notified of August 10 Court Deadline - ACCESS Newswire

Jun 12, 2026

Jun 11, 2026

ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence - Stocktwits

Jun 11, 2026

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - lincolnjournal.com

Jun 11, 2026

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire

Jun 11, 2026

INVESTOR ALERT: Securities Class Action Filed Against ADMA Biologics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP - mydailyrecord.com

Jun 11, 2026

ADMA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - Bluefield Daily Telegraph

Jun 11, 2026

Law Offices of Howard G. Smith Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action - lincolnjournal.com

Jun 11, 2026

$ADMA Breaking News: ADMA Biologics Sued for Securities Fraud after Channel Stuffing Claims Lead to 16% Stock Drop – Investors Notified to Contact BFA Law - The Malone Telegram

Jun 11, 2026

ADMA INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire

Jun 11, 2026

Jun 10, 2026

Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit - Business Wire

Jun 10, 2026

Class Action Lawsuit Filed Against ADMA Biologics - Intellectia AI

Jun 10, 2026

ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel ... - Caledonian Record

Jun 10, 2026

ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities Fraud; Investors Should Contact Block ... - Caledonian Record

Jun 10, 2026

ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities - GlobeNewswire

Jun 10, 2026

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ADMA Biologics, Inc. Investors – ADMA - The Joplin Globe

Jun 10, 2026

Raymond James Initiates ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $21 - Moomoo

Jun 10, 2026

ADMA: Analyst Upgrades Stock with $21 Price Target - GuruFocus

Jun 10, 2026

Raymond James initiates ADMA Biologics stock coverage with outperform rating - Investing.com Nigeria

Jun 10, 2026

ADMA Biologics Investigation: ADMA Biologics (ADMA) - GlobeNewswire

Jun 10, 2026

Jun 08, 2026

(ADMA) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Jun 08, 2026